Boutique Venture Partners

Delfina operates a data-driven prenatal care system designed to enhance maternal and infant safety during pregnancy. The company employs machine learning models to optimize interventional workflows and create personalized care plans based on patient risk factors, thereby facilitating early interventions and improving provider efficiency. This approach aims to deliver equitable and cost-effective pregnancy care within the healthcare industry.

Operator of a SaaS-based healthcare price transparency platform intended to aggregate and contextualize price transparency, insurance, and demographic data. The company's platform offers health plans a simple way to comply with the CMS (Centers for Medicare and Medicaid Services) price transparency legislation while digitizing how patients shop, book, and pay for healthcare, enabling users to realize average cost savings to guide every healthcare purchasing decision.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

FluidAI Medical is a medical platform company focused on enhancing global patient care through the innovative application of artificial intelligence in post-operative recovery. The company has developed a smart catheter system that fosters a proactive approach to post-operative care delivery. By utilizing data generated within the body, FluidAI's platform aids in the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. This technology aims to improve patient outcomes and streamline the management of post-operative recovery processes.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies to diagnose and treat glaucoma, a leading cause of irreversible blindness. The company’s flagship product, miLens, is a novel eye pressure monitoring contact lens designed to provide a non-invasive and convenient solution for continuous intraocular pressure (IOP) monitoring. This technology addresses a critical need, as a significant portion of glaucoma patients remain undiagnosed, and many experience vision loss despite treatment. miLens utilizes a unique, electronics-free sensor technology, which is protected by an extensive portfolio of patents. In addition to IOP monitoring, Smartlens is exploring applications for its technology in neurological disorders and cancers at Stanford University Labs. The company also possesses a non-invasive drug delivery system that not only monitors IOP but also releases medication as needed, enhancing treatment efficacy and patient compliance. Smartlens has received recognition for its innovation, including awards for outstanding achievements in medical technology, and has been featured in various prominent media outlets.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

Delfina operates a data-driven prenatal care system designed to enhance maternal and infant safety during pregnancy. The company employs machine learning models to optimize interventional workflows and create personalized care plans based on patient risk factors, thereby facilitating early interventions and improving provider efficiency. This approach aims to deliver equitable and cost-effective pregnancy care within the healthcare industry.

CuraFi is a healthcare delivery and management company that specializes in providing specialty infusion services for patients with complex medical conditions. The company has developed an integrated specialty pharmacy and care delivery payment platform aimed at enhancing affordability and access to specialty medications. By aligning physicians and payers, CuraFi's platform helps manage patient costs and reduce medication expenses, while offering predictable payment structures on a per member per month basis. This approach enables healthcare centers to deliver life-saving medications and improve continuity of care, ultimately leading to better patient outcomes and new revenue opportunities for independent providers.

FluidAI Medical is a medical platform company focused on enhancing global patient care through the innovative application of artificial intelligence in post-operative recovery. The company has developed a smart catheter system that fosters a proactive approach to post-operative care delivery. By utilizing data generated within the body, FluidAI's platform aids in the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. This technology aims to improve patient outcomes and streamline the management of post-operative recovery processes.

Filtricine, Inc., founded in 2017 and based in Santa Clara, California, is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company's approach involves targeted nutrient deprivation, which identifies and exploits metabolic vulnerabilities specific to cancer cells. By depleting nutrients critical to cancer growth without using traditional drugs, Filtricine aims to provide effective treatments that minimize harm to healthy cells.

miRecule, Inc. is a biotechnology company focused on developing innovative therapies for cancer and muscular dystrophy through its proprietary microRNA-based drug discovery platform, DREAmiR. Founded in 2016 and based in Gaithersburg, Maryland, the company leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. This platform integrates genomic sequencing, expression, and prognostic data to identify candidates for microRNA replacement therapy, enabling the creation of tailored RNA therapeutics that can directly target and rectify these genetic issues. miRecule's research is aimed at developing first-in-class therapies, with current lead programs addressing Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy. Through its advanced approach, miRecule aims to provide solutions that help patients overcome the debilitating effects of their conditions.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

FluidAI Medical is a medical platform company focused on enhancing global patient care through the innovative application of artificial intelligence in post-operative recovery. The company has developed a smart catheter system that fosters a proactive approach to post-operative care delivery. By utilizing data generated within the body, FluidAI's platform aids in the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. This technology aims to improve patient outcomes and streamline the management of post-operative recovery processes.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, focused on developing innovative therapies for bone-related diseases. Established in 2013, the company specializes in a prodrug platform that delivers therapeutics selectively to bone, addressing challenges associated with conventional drug delivery methods. Mesentech's lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic that aims to reverse bone loss associated with conditions such as osteoporosis and Duchenne muscular dystrophy. The company's proprietary technology enhances the delivery of small-molecule and biological drugs to the bone's surface and interior, allowing for more effective treatment while minimizing side effects. This approach is particularly significant given the inherent difficulty in accessing bone tissue due to its hard surface and low porosity. Mesentech's focus on selective drug delivery not only aims to improve treatment efficacy but also hopes to accelerate bone healing and address complications associated with low bone density disorders.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

miRecule, Inc. is a biotechnology company focused on developing innovative therapies for cancer and muscular dystrophy through its proprietary microRNA-based drug discovery platform, DREAmiR. Founded in 2016 and based in Gaithersburg, Maryland, the company leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. This platform integrates genomic sequencing, expression, and prognostic data to identify candidates for microRNA replacement therapy, enabling the creation of tailored RNA therapeutics that can directly target and rectify these genetic issues. miRecule's research is aimed at developing first-in-class therapies, with current lead programs addressing Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy. Through its advanced approach, miRecule aims to provide solutions that help patients overcome the debilitating effects of their conditions.

QMENTA is a company specializing in medical imaging software solutions. It offers a cloud-based platform designed to assist doctors in diagnosing and treating patients with brain diseases. The platform provides tools for managing and analyzing medical images, including patented AI-powered algorithms that help process large-scale brain image data efficiently and cost-effectively. QMENTA's services support various applications such as clinical trials, neuroimaging disease packages, and research in neurology.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies to diagnose and treat glaucoma, a leading cause of irreversible blindness. The company’s flagship product, miLens, is a novel eye pressure monitoring contact lens designed to provide a non-invasive and convenient solution for continuous intraocular pressure (IOP) monitoring. This technology addresses a critical need, as a significant portion of glaucoma patients remain undiagnosed, and many experience vision loss despite treatment. miLens utilizes a unique, electronics-free sensor technology, which is protected by an extensive portfolio of patents. In addition to IOP monitoring, Smartlens is exploring applications for its technology in neurological disorders and cancers at Stanford University Labs. The company also possesses a non-invasive drug delivery system that not only monitors IOP but also releases medication as needed, enhancing treatment efficacy and patient compliance. Smartlens has received recognition for its innovation, including awards for outstanding achievements in medical technology, and has been featured in various prominent media outlets.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Frontier Bio Corporation is a biotechnology company based in Oakland, California, focused on developing and manufacturing advanced bioprinting technologies. Founded in 2018, the company specializes in creating lab-grown human tissues as an ethical alternative to animal studies. Its flagship product, the FLUX-1, is a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This device enables the bioprinting of complex tissues such as skin, cartilage, and bone, and allows for applications in drug toxicity testing, tissue implants, drug screening, disease modeling, and prosthetics. By providing a means to produce human tissues with complete cell survivability, Frontier Bio aims to enhance the healthcare industry's ability to replace animal testing and address the organ transplant waitlist.